Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Alliance Pharma And 2 Other UK Penny Stocks With Promising Fundamentals

In This Article:

The United Kingdom's stock market has been facing challenges, as evidenced by the recent declines in the FTSE 100 and FTSE 250 indices, partly due to weak trade data from China affecting global economic sentiment. Despite these broader market pressures, investors can still find opportunities by focusing on stocks with strong fundamentals. Penny stocks, although sometimes seen as a relic of past trading days, offer potential for significant returns when they are grounded in solid financials. In this article, we explore three UK penny stocks that stand out for their robust balance sheets and potential for growth.

Top 10 Penny Stocks In The United Kingdom

Name

Share Price

Market Cap

Financial Health Rating

Foresight Group Holdings (LSE:FSG)

£3.91

£445.66M

★★★★★★

Warpaint London (AIM:W7L)

£3.58

£289.22M

★★★★★★

Next 15 Group (AIM:NFG)

£3.135

£311.79M

★★★★☆☆

Begbies Traynor Group (AIM:BEG)

£0.94

£149.81M

★★★★★★

Polar Capital Holdings (AIM:POLR)

£4.725

£455.47M

★★★★★★

Helios Underwriting (AIM:HUW)

£2.21

£157.67M

★★★★★☆

Secure Trust Bank (LSE:STB)

£4.26

£81.24M

★★★★☆☆

Van Elle Holdings (AIM:VANL)

£0.39

£42.2M

★★★★★★

Ultimate Products (LSE:ULTP)

£0.805

£68.33M

★★★★★★

Luceco (LSE:LUCE)

£1.468

£226.41M

★★★★★☆

Click here to see the full list of 445 stocks from our UK Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Alliance Pharma

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Alliance Pharma plc acquires, markets, and distributes consumer healthcare products and prescription medicines across various regions including Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas with a market cap of £334.07 million.

Operations: The company's revenue is derived from two main segments: Consumer Healthcare, which generated £136.21 million, and Prescription Medicines, contributing £46.93 million.

Market Cap: £334.07M

Alliance Pharma plc, with a market cap of £334.07 million, is undergoing significant changes as it faces a takeover by a consortium led by DBAY Advisors. The acquisition will result in its delisting from AIM, expected in the first half of 2025. Despite being unprofitable and experiencing increased losses over five years, Alliance's interest payments are well covered by EBIT and operating cash flow effectively covers debt. Its management team is seasoned with an average tenure of 7.4 years, although the board lacks experience with only 1.3 years on average per member. Short-term assets exceed short-term liabilities but fall short against long-term obligations.